Molecular pathways and targets in cancer-related inflammation

References

• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
   PubMed Web of Science ®Google Scholar
• Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, . NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807–11.
   PubMed Web of Science ®Google Scholar
• Mantovani A. Cancer: Inflaming metastasis. Nature. 2009;457:36–7.
   PubMed Web of Science ®Google Scholar
• Borrello MG, Alberti L, Fischer A, Degl’innocenti D, Ferrario C, Gariboldi M, . Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A. 2005;102:14825–30.
   PubMed Web of Science ®Google Scholar
• Russell JP, Engiles JB, Rothstein JL. Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol. 2004;172:4059–67.
   Google Scholar
• Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M, Rothstein JL. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemo-tactic factors. Oncogene. 2003;22:4569–77.
   PubMed Web of Science ®Google Scholar
• Cerutti JM, Oler G, Michaluart P Jr, Delcelo R, Beaty RM, Shoemaker J, . Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res. 2007;67:7885–92.
   PubMed Web of Science ®Google Scholar
• De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, . Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res. 2007;67:11821–9.
   Google Scholar
• Xu K, Shu HK. EGFR activation results in enhanced cycloox-ygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 2007;67:6121–9.
   PubMed Web of Science ®Google Scholar
• Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, . MlP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 2006;108:3465–71.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, . CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941–51.
   PubMed Web of Science ®Google Scholar
• Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, . Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291–302.
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203:1651–6.
   PubMed Web of Science ®Google Scholar
• Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211–8.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–7.
   PubMed Web of Science ®Google Scholar
• Kobielak A, Fuchs E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A. 2006;103:2322–7.
   Google Scholar
• Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, . The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med. 2008;205:1155–71.
   PubMed Web of Science ®Google Scholar
• Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006;66:10671–6.
   PubMed Web of Science ®Google Scholar
• Markowski MC, Bowen C, Gelmann EP. Inflammatory cytokines induce phosphorilation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res. 2008;68:6896–901.
   PubMed Web of Science ®Google Scholar
• Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, . Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1 + CD 11 b + myeloid cells that promote metastasis. Cancer Cell. 2008;13:23–35.
   PubMed Web of Science ®Google Scholar
• Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, . DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 2008;118:2516–25.
   PubMed Web of Science ®Google Scholar
• Campregher C, Luciani MG, Gasche C. Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA) 13-repeat in colon epithelial cells. Gut. 2008;57:780–7.
   Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51.
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, . IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–50.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, . IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.
   PubMed Web of Science ®Google Scholar
• Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, . RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007;131:309–23.
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, . NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, . Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory members of the IL-1 receptor family. Cancer Res. 2007;67:6017–21.
   PubMed Web of Science ®Google Scholar
• Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, . The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumori-genesis. Immunity. 2007;26:461–75.
   PubMed Web of Science ®Google Scholar
• Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, . Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med. 2008;205:1879–88.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, . A distinct and unique transcriptional programme expressed by tumor-associated macrophages: defective NF-kB and enhanced IRF-3/STAT1 activation. Blood. 2006;107:2112–22.
   PubMed Web of Science ®Google Scholar
• Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, . ‘Re-educating’ tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205:1261–8.
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, . Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–21.
   PubMed Web of Science ®Google Scholar
• Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, . Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999;5:828–31.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.
   PubMed Web of Science ®Google Scholar
• Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, . Blocking TNF-alpha in mice reduces color-ectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560–70.
   PubMed Web of Science ®Google Scholar
• Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, . The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67:585–92.
   PubMed Web of Science ®Google Scholar
• Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, . Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008;27:1671–81.
   PubMed Web of Science ®Google Scholar
• Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, . Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542–9.
   PubMed Web of Science ®Google Scholar
• Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, . Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 2008;111:5054–63.
   PubMed Web of Science ®Google Scholar
• Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, . Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res. 1990;50:4771–5.
   PubMed Web of Science ®Google Scholar
• Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, . Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446:690–4.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.
   PubMed Web of Science ®Google Scholar
• Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, . Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649–56.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315–22.
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.
   PubMed Web of Science ®Google Scholar
• Kim S, Takahashi H, Lin W-W, Descargues P, Grivennikov S, Kim Y, . Carcinoma produced factors activate myeloid cells via TLR2 to stimulate metastasis. Nature. 2009;457:102–6.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307–13.
   PubMed Web of Science ®Google Scholar
• Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, . Interleukin-1 beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67:1062–71.
   Google Scholar
• Shchors K, Shchors E, Rostker F, Lawlor E, Brown-Swigart L, Evan G. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006;20:2527–38.
   PubMed Web of Science ®Google Scholar
• Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, . Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008;14:156–65.
   PubMed Web of Science ®Google Scholar
• Marhaba R, Nazarenko I, Knofler D, Reich E, Voronov E, Vitacolonna M, . Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. Int J Cancer. 2008;123:134–45.
   Web of Science ®Google Scholar
• Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, . Host-derived interleukin-1 alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J Immunol. 2009;182:4874–81.
   Google Scholar
• Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13:851–6.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, . Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.
   PubMed Web of Science ®Google Scholar
• Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, . Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006;124:615–29.
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–83.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109–19.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115–30.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, . Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131–44.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S, Maeda S, Kim KH, Elsharkawy AM, . Gender disparity in liver cancer due to sex differences in MyD88-dependent-IL-6 production. Science. 2007;317:121–4.
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317:124–7.
   PubMed Web of Science ®Google Scholar
• Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, . Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117:3846–56.
   PubMed Web of Science ®Google Scholar
• Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, . IL-6 triggers malignant features in mam-mospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988–4002.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell. 2008;13:7–9.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, . IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.
   PubMed Web of Science ®Google Scholar
• Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, . gp130-Mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91–102.
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, . Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114–23.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.
   PubMed Web of Science ®Google Scholar
• Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, . The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest. 2007;117:1884–92.
   Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
   PubMed Web of Science ®Google Scholar
• Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, . Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008;111:5457–66.
   Google Scholar
• Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, . The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008;68:9060–9.
   Google Scholar
• Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, . HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206–20.
   PubMed Web of Science ®Google Scholar
• Seandel M, Butler J, Lyden D, Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell. 2008;13:181–3.
   PubMed Web of Science ®Google Scholar
• Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13:193–205.
   PubMed Web of Science ®Google Scholar
• Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, . Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008;68:4340–6.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z, . Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181:346–53.
   PubMed Web of Science ®Google Scholar
• Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, . Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110:4319–30.
   PubMed Web of Science ®Google Scholar
• Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, . Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007;67:6433–41.
   PubMed Web of Science ®Google Scholar
• Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, . Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67:5708–16.
   PubMed Web of Science ®Google Scholar
• Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 2008;68:34–43.
   Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–31.
   PubMed Web of Science ®Google Scholar
• Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, . Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol. 2008;180:7175–83.
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, . Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463–75.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, . Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25:911–20.
   PubMed Web of Science ®Google Scholar
• Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, . Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205:1673–85.
   PubMed Web of Science ®Google Scholar
• Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008;27:31–40.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155–61.
   PubMed Web of Science ®Google Scholar
• Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008;123:780–6.
   PubMed Web of Science ®Google Scholar
• Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, . Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 2008;68:18–21.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784–9.
   PubMed Web of Science ®Google Scholar
• Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, . Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood. 2008;111:4764–70.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, . The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.
   PubMed Web of Science ®Google Scholar
• Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, . Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 2007;99:1257–69.
   PubMedGoogle Scholar